Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Viracta Therapeutics Inc (RYIG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Viracta Therapeutics historical data, for real-time data please try another search
1.150 +0.080    +7.48%
02/10 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US92765F1084 
S/N:  A2ARHW
  • Volume: 1,750
  • Bid/Ask: 0.998 / 1.018
  • Day's Range: 1.090 - 1.150
Viracta Therapeutics 1.150 +0.080 +7.48%

Viracta Therapeutics Inc Company Profile

 
Get an in-depth profile of Viracta Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

40

Equity Type

ORD

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Contact Information

Address 2533 South Coast Highway 101 Suite 210
Cardiff, 92007
United States
Phone 858 400 8470
Fax -

Top Executives

Name Age Since Title
Ivor Royston 78 2007 Director
Thomas Eric Darcy 73 2021 Independent Director
Stephen Rubino 66 2021 Independent Director
Barry J. Simon 59 2021 Independent Director
Mark Andrew Rothera 61 2022 CEO, President & Director
Roger James Pomerantz 67 2020 Independent Chairman of the Board
Robert Baiocchi - 2018 Member of Scientific Advisory Board
Ronald Levy - 2018 Member of Scientific Advisory Board
Jane F. Barlow 63 2021 Independent Director
Daniel Douglas Von Hoff 76 - Member of Scientific Advisory Board
Lawrence S. Young - 2018 Member of Scientific Advisory Board
Pierluigi Porcu - 2018 Member of Scientific Advisory Board
Flavia Borellini 65 2021 Independent Director
Samuel Lafayette Murphy 46 2019 Independent Director
Carl H. June 70 2018 Member of Scientific Advisory Board
Gavin Giovannoni - 2024 Member of Scientific Advisory Board
Shannon Kenney - - Member of Scientific Advisory Board
Jane Chung 52 2022 Independent Director
Douglas V. Faller - - Scientific Founder & Chairman of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VIRX Comments

Write your thoughts about Viracta Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Efren Lopez
Efren Lopez Mar 31, 2021 3:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Has anyone else seen the sec filings on company site 5-6 major sec filinggs for purchase of over 80k shares filed 3/30
AP Cushman
AP Cushman Mar 02, 2021 7:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pump and dump scheme, only made the private officers of Viracta rich on acquiring Sunesis pharma
AP Cushman
AP Cushman Feb 25, 2021 12:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Going to reverse split 1:3.5 when it goes live again.
ridzuan jalil
ridzuan jalil Feb 25, 2021 10:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
today its change to merge VIRX
AP Cushman
AP Cushman Feb 24, 2021 2:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If you like this stock, load up on MATn while it's cheap. A lot of development in the works, then most likely a move up to NASDAQ
ridzuan jalil
ridzuan jalil Feb 24, 2021 7:58AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yesterday dip to 3.63..today pre market $5.00... woww
Marco Garrido
Marco Garrido Nov 30, 2020 9:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cocrystal Pharma, Inc. (NASDAQ:COCP) was in 4 hedge funds' portfolios at the end of the third quarter of 2020. The all time high for this statistics is 3. This means the bullish number of hedge fund positions in this stock currently sits at its all time high. COCP has experienced an increase in hedge fund interest recently. There were 1 hedge funds in our database with COCP holdings at the end of June. Our calculations also showed that COCP isn't among the 30 most popular stocks among hedge funds  Premarket, +10%
Florin Tudor
Florin Tudor Nov 30, 2020 7:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
wow!!wat is going on!!skyrocket
Khalid Zms
Khalid Zms Sep 24, 2020 9:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No body talks
Nasir DON
Nasir DON Sep 24, 2020 9:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Here i am
Krypto Nite
Krypto Nite Sep 07, 2020 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I hear JP Marlin is the boile- I mean investment firm that sells the most of this stock.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email